Latamoxef

The continuous rise in drug resistance of Gram-negative bacteria has led to an increasing clinical demand for broad-spectrum, β-lactamase-resistant β-lactam antibacterial drugs. As a representative variety of oxacephem antibiotics, latamoxef exerts a bactericidal effect by inhibiting the biosynthesis of bacterial cell walls, and has strong antibacterial activity against Gram-negative bacteria and anaerobic bacteria. Meanwhile, it is highly stable to β-lactamase. Clinically, it is mainly used for sepsis, meningitis, respiratory tract infections, biliary tract infections, abdominal infections, genitourinary system infections, skin and soft tissue infections, etc. caused by sensitive bacteria, especially for moderate to severe infections caused by drug-resistant Gram-negative bacteria. It is an important option for anti-infective treatment in departments such as ICU and surgery.

At present, the domestic market size of latamoxef has exceeded 2 billion yuan, with a compound annual growth rate of approximately 12% in the past three years. The growth momentum mainly comes from the increased demand for diagnosis and treatment of drug-resistant bacterial infections and the improvement of the standardization of antibacterial drug use in primary medical institutions under hierarchical diagnosis and treatment. In terms of the competitive landscape, the original research product still accounts for about 45% of the market share. The number of approved domestic generic drugs has gradually increased in recent years. After the implementation of centralized procurement, the price has dropped by approximately 62%, which further promotes the clinical accessibility of the drug, and the market share of generic drugs is continuously increasing.

The original research enterprise of latamoxef is Shionogi Pharmaceutical Co., Ltd. of Japan, with the original brand name "Shiomarin". Its core compound patent expired in 2009. At present, the main dosage form marketed in China is latamoxef sodium for injection, with common specifications of 0.25g, 0.5g and 1.0g. The original product and generic drugs produced by many domestic enterprises have been included in the national reference preparation catalog. According to the domestic API registration platform, 3 enterprises have obtained A-status registration numbers for latamoxef APIs through the associated evaluation with preparations, and the registration applications of another 2 enterprises are under evaluation. A number of domestic generic latamoxef sodium preparations have been approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for latamoxef API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers and preparation R&D institutions for impurity research and quality control related work.